Ilian Iliev
CEO at EMV CAPITAL PLC
Replay available
Financial Results for the year ended 31st December 2024 hosted by EMV Capital (LSE:EMVC) on Investor Meet Company, held 2025-06-12.

On 6ix: 6ix.com/event/emv-capital-plc-emvc-financial-results-for-the-year-ended-31st-december-2024
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:00 Good morning, and welcome to the EMV CAPITAL PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time by the q and a tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. And I'd now like to hand you over to Ilian Iliyev, CEO. Good morning,
0:31 sir. Good morning, and thank you all for joining us for the presentation of our annual results for 2024. I'm Ilyan Ilyan, the CEO of EMV CAPITAL PLC, and I'm joined by Ed Cooper, executive director at EMV CAPITAL PLC and general counsel. So there's a lot to go through this morning, and I just wanna flag the presentation will be available on our website and, of course, on IMC after this call. So if you don't manage to pick up everything, you know, you'll be able to refer to it. But look. I mean, as as you know, it's been a complex year in the markets, and we have some exciting and interesting updates at EMV CAPITAL level. But before I get into those, for those of you who have had less exposure to our story, I want to remind you of what we're about.
1:21 We for the last few years, we've been building up a vision to be a leading VC investment group in the deep tech and life sciences sector in primarily focused on The UK with some international exposure. We're focused on companies that are IP intensive, that are real, that have real impact in the world. And as you'll see in the next slides, we have, over the last few years, built up AUM of roughly 100,000,000, of which 38,000,000 is on balance sheet. We now have a relatively large portfolio for 70 plus companies, and we're quite ambitious. We're now driving towards the next milestone in our journey of 200,000,000 assets under management. Last year, we got our direct FCA authorization, which enabled us to launch the fund management practice. And I guess, again, you'll hear a lot more about each of these aspects shortly.
2:12 A little bit about our model. So while we are a VC, we are also focused on generating fees on an ongoing basis. We live in a complex world. We believe that the old model of doing venture capital is changing. And the way we have developed the business over the last few years is we have recurring fees from fund management. We also have corporate finance fundraising fees through our FCA authorized subsidiary, and we also have a value creation services business, which again generates fees. This is to help us pay our way through life. Ultimately, what makes things exciting is the exits and carried interest we get from the portfolio as companies mature and exit. So within our model, these several blocks enable us provide us with something that we think is somewhat unique in this space.
3:03 The corporate finance side of the business enables us to facilitate and syndicate external investment for our portfolio companies, which in turn enables the companies to execute their growth plans. The venture the value creation services side helps not all companies, but a cohort of companies who find themselves at the pivot or at a changing situation for us to provide some resources so that they can move to the next. We're helping them with investments and exit readiness. Can be helping them evolve or pivot their business and financial strategy. It can be us helping them to build or rebuild their leadership teams. But the combination of the money and the value creation services we found is quite quite a strong combination.
3:48 I'll talk a bit later about our venture building practice that combines these two functions that has led to significant fair value growth over the last few years. At any rate, across all of these companies, whether we are engaged in this or not, we have a proactive approach where we engage with the company's boards and their co investors protecting value and driving returns. And as I flagged earlier, ultimately, this is around realizing capital returns and carried interest returns as the companies go go towards exit. A little bit about the growth in assets under management. So this this has multiple benefits for the business. Of course, it it scales our recurring management fees. It increases the potential for the carried interest, but also it helps us increase our firepower for the existing portfolio and new additions that we might have in the future.
4:40 Now there's several components of our AUM growth. And, again, through the next slides, you'll see what that translates into numbers. There is the EMV CAPITAL balance sheet investments themselves. Now we tend to use cash very sparingly, but we use services as a way of building up our our position and sometimes cash. We have a naturally growing third party managed side of the business with through our ever growing investor syndicate, and I know some of you are on this call. We want to thank you for your continued support. That has a natural growth rate. We raise in the order of 8 to 10,000,000 a year from that side of the business. We also added the Cambridge based Maplet Capital Fund last year May. So that in itself has grown our business, but there are some initiatives around that. We have also taken over the management of our EAS fund, which again has growth potential through IFAs and wealth managers, and there are other fund initiatives that we're developing. So what I want to emphasize here, it's not it's not one short on goal.
5:39 It's multiple short on goal for us to grow our AUM AUM to that 200,000,000 mark I flagged earlier. Now in today's environment, there have been a lot of speculation in the market about where AIM is going and where the companies on AIM are going, and you've seen some of them where they went naturally like any other business important and sometimes hard discussions at board level. Where we stand is actually we feel for us as a VC, actually being on name is a differentiator and an advantage. So over the last year, we have made given the circumstances, we feel quite productive use of our quotation. In December last year, we we had the 1,500,000 placements at the 15% premium. Again, And, I wanna thank those of you on that. We really appreciate your support.
6:26 But we've also used our shares smartly, we think, to anchor an investment round in Qbot, which has been undergoing a transition. We did that at the premium. We've been able to issue shares to suppliers or strategic parties, keeping the cash on the balance sheet secure, but still engaging those people and aligning them with our own interests. But what we've also found is talking to both UK and non UK institutional corporate to family office investors is that being named, being audited, and, of course, being FCA authorized gives us an institutional great feel and transparency of the governance to other investors in our fund structure in in EMV CAPITAL itself is, of course, but other partners we're building in. So we we feel that will continue to be important for us. Last but not least, it provides management team incentivization.
7:18 Having said all of that, the market remains tough. The market remains with challenges, but we believe that we are well positioned to benefit from the various Mansion House initiatives, both at PLC and fund management level. What we do is exactly what National House says UK POCs and UK VCs should be doing, backing UK industrial capabilities. Our shareholder base is loyal. I would say there's been several shareholders that have increased their exposure over the last year, and the directors in PDMRs hold a relatively significant 17% of the of the business. I won't speak too much here about the portfolio. I've got a few case studies later on. But what what I'll flag is that with our portfolio has been remarkably resilient over the last few years in terms of portfolio survival and growth rate. Again, this is a function of our proactive approach.
8:14 And with of the market capital portfolio, we now have exposure both to the ecosystem and the specific assets of some of The UK's best VC backed companies. Companies such as Cambridge Gun Devices, Echion, New Quantum, Paragraph, and others, these are some of the best of what The UK has to has to offer. And, accordingly, both our current both our traditional portfolio and the EMV CAPITAL portfolio have attracted significant third party funding, 105,000,000 from our legacy portfolio, and the market capital portfolio has attracted 171,000,000. So across both of those, this is more than a 250,000,000 that has been been attracted by our portfolio. It wasn't all us. We did a small part of that. But I think what it shows is that while the VC markets have been really challenged, we happen to be operating in a part of the market that is active, that with investors that is seeing market growth.
9:12 So that's the high level picture, but let's get into the numbers. So, look, we've had a diverse but ultimately successful year. Group revenues have increased by 70% to 2,500,000 from 1,400,000 last year. But within our model, because we because of the way we account, we differentiate between what we call as the core. So that's PLC EMV CAPITAL PARTNERS, which is the the the the FCA authorized part and other operating parts of the the company. This is where the business is. And the number is companies the way we happen to that that happen to be accounted to subsidiaries, but those companies are funded by other investors. So we consolidate the losses and the revenues, but from balance sheet perspective, what we focus on is on the core.
9:59 So in terms of the core, we've had 67% increase in the core revenues to 2,000,000 from 1,200,000 last year. That has that is covering roughly 58% of the core costs. And turning to the losses, the loss of the core has increased slightly to 1,500,000 from 1,100,000. That's partly accounted for the consolidation of the MATLAB capital management side of the business, a lot of which is now set pretty synergistic. And the other losses are accounted for by the by the subsidiaries. And, again, I emphasize that the the subsidiaries, Paraxes, Glycotest, are almost entirely funded by third party investment, so it's not a burden on the balance sheet.
10:45 Now if you take a deep dive within the the group revenue, you will see this steady growth in our revenues since management team took over in 2020. If you recall, what was then called Net Scientific PLC acquired EMV CAPITAL, which is the company I led, and we brought with us our management approach. And since then, we've seen a good trend in terms of the revenues generated in the business. This is split roughly three ways between fund management, fundraising fees, and services, And we believe there is a scope growth from each of these channels in their own different ways. I talked about how we plan to grow our AUM business, so that's how fees will grow there. The corporate finance fees, look, we've generate we've we've syndicated with $86,000,006,000,000 pounds of fresh cash into our businesses. This is money that goes under our custodian with carried interest exposure, which is higher than the previous year. Remember, this is in the middle of a bear market. We're in a very challenging market. So we believe that if as the markets improve, there's significant upside for the corporate finance side of our business. And, of course, there's the recurring value creation services from the portfolio which has scope for growth.
11:55 Now if we look at the fair value growth of the direct holdings, this is, again, this is what we hold on balance sheet. And over the last few years, you can see that this has had a steady growth. What has happened if you compare the high in 2022 versus '24 is in 2024 to '22, PDS Biotech, our Nasdaq holding had a particularly good year, and they had a very high valuation. But since then, the portfolio has balanced out whereby the port privately held portfolio, I. E. Not listed companies, has grown significantly. Through this period, we have deepened our stakes, and we have added some some some some new holdings in new companies in that space. So we think that now, compared to a few years ago, this is a much more diversified and therefore stable direct fair value with significant scope for growth.
12:46 This will naturally grow simply because the companies are growing in value, not all of them, but the majority of them have grown in the last year. We also find that opportunities to deepen our stakes in favorable terms as the companies normalize the Finally, we anticipate adding new companies with direct balance sheet exposure. Now turning to the managed assets under management, this is where the fund management practice is. That, again, has grown quite significantly, 43% CAGR since since the end of two thousand and twenty, the acquisition of EMV CAPITAL in that year. So, again, here, we expect a natural growth in our AUM. Of course, there's volatility, but the managed companies, the gas fund practice is growing organically at the rate of 8 to £10,000,000 a year. And finally, we're looking at new fund launches to continue to drive AUM.
13:35 So both measures of fair value, direct and managed, we anticipate will continue to grow simply because of the model we have set up that has its own momentum. In terms of fair value composition, you'll see here the direct assets are 37,000,000. The balance is managed. Market capital naturally represents a significant part of that, And we anticipate the ES fund will accelerate growth as as IFS and wealth managers become on ramp onto it. In terms of the specific companies, again, if you looked at this pie two years ago or earlier, there was a lot of concentration of one or two assets. I'm just flagging here that it's quite diverse right now. Now this is a important analysis.
14:23 Our current market cap is around 12,200,000 at 47 p per share. For our NAV, we are we are not include the accounting measures do not include the the the value of the subsidiaries due to direct consolidation. And in the annual accounts, that is that is explained. So what we've done this year is we have done an adjusted NAV to show you if we were to account or once we do account for the for the subsidiary companies, what happens to the adjusted NAV and what happens to the adjusted NAV per share. And we've also then looked at the direct fair value, what the direct fair value per share is. So what you can see is that even on these static measures, there is significant value simply not captured in the current NAF per share, and the gap between the two is really quite substantial.
15:18 We believe as management that even that is somewhat of an understatement because it does not capture the embedded goodwill within the operating businesses. We're generating recurring revenues from fund management fees and value creation services. If it were a different business, that would have value in itself. There's the future carried carried interest from fund performance. And, of course, there is the expected growth in the underlying portfolio. Now we're using PVCA methodology methods and all the same questions on our methodology. That's naturally historically looking. It's what has happened so far. So these measures do not include what might happen in the future, which could be negative and positive, of course, but we're management, so we're we're optimistic. So we believe quite strongly that as a result of the current market capitalization is significantly understand under underestimating the group's real value. And, of course, we want to communicate this gap or this believed gap better with with the market.
16:15 I've talked a lot about the market capital mandate we acquired last year. Again, this didn't come out of nowhere. We have been close to the market capital team and investors for many years. Before that, we played a role when that was spun off from Marshall Aerospace from Marshall Group. But last year, we took over as fund managers, as you know, and that has provided it was a paper transaction. It was very effective, capital efficient for for EMV CAPITAL shareholders. It has provided us with this additional AUM. I also talked about the portfolio of companies that this has provided us and the multiple shots and goals we have now. But over the last year, we have worked closely with the with the team at Martlet who are now fully integrated in EMV CAPITAL and building out our exposure to the Cambridge and international ecosystem around the Cambridge high-tech network.
17:06 Another effect for those of you who know the place is that we have shortened the height of King's College Cathedral. That's a bit of a image manipulation there. But in terms of on a go forward basis, we're looking at continued AUM growth of that asset, but also the opportunities that come out of of Market Capital's co investment for our US practice and the potential for raising a new fund. Just under a month ago, we let we let an additional investment into market capital, giving it a bit of more working capital and dry powder. And, again, we're continuing to grow in this space. Now I talked about our venture build practice. I'm gonna spend a little bit of time explaining what we do here. As a PLC rather than a plain vanilla VC fund, we have multiple tools we can use. We can use PLC balance sheet. We can use paper. We're able to anchor investment rounds. We're able to have a service site that's not that's not part of the the fund management.
18:04 And we have used this multifaceted strategy to engage with a cohort of companies, which you'll see in the next slide, to go in when the valuation was at a attractive position. The companies had certain issues to be resolved, and we used the combination of our corporate finance side and value creation services side to help those companies pivot, clean up their model, attract funding to them, and crystallize value. We are going to continue to do that. So we're targeting companies that are IP rich with somewhat validated IP, perhaps not in high revenues, but visibility towards that, who need the strategic redirection. We restructure those companies. It can be a cleanup of the cap table. It can be us providing cash in kind, but we get direct exposure to to the equity there.
18:51 And we then help them grow.
18:54 Using that model of the this is over the last within the last three years, basically, we have invested £400,000 in cash, about 500,000 of in kind services, and we've generated 8,500,000 of fair value. Now admittedly, this is paper. We haven't had exits. The ultimate proof is the exits. Nevertheless, this is fair value validated by third party investment, and we feel that's quite a unique story, something we're able to do. And the reason we're able to do it is because of everything else that we do. It gives us all these different tools. It's a very capital efficient model with stronger, better upside, and we'll continue to do it with selectively with various companies. In terms of the businesses, this includes Deep Tech Recycling, a plastic waste, chemical pla chemical plastic waste recycling that I've talked about before, denamed it in the lab space, Ventev, heat pump developer, Vortex, liquid biopsy, Wanda Health.
19:46 Now we've had some exposure to this some of these companies for a while. What we're talking about here is when we gained the direct exposure. 21% Deep Tech, 30%, DNAMet, Ventev, 10%, Vortex, 22%, Wanda, 21%. And you can see for some of those companies, we've been monitoring for a while when we found the right place to to to gain exposure, which was within the last few years. So we feel we feel quite positive about this story. It's not once. It's not twice. Five times we've done it with five different companies, and we're going to do do more of the same.
20:20 What's also worth flagging in the next few slides is that the combined direct fair value of these companies exceeds our current market cap, which again is a different way of looking at at the mark the gap between current market cap and the underlying value of EMV CAPITAL. I've spoken about each of these companies in previous presentations. So here, I'll just focus on the developments over the last year and and and six months. So SoftBank Technologies, which is an Edinburgh spin out over the last eighteen months, they have advanced their collaboration with ViaSat. The space itself is really exciting. Perhaps for the wrong reasons, the war in Ukraine has shown the importance of drone and aerobond platforms, but also just in general, satcoms as a part of the mainstream telecommunication systems has has really had the breakthrough. As a result, the company is experiencing a lot of external interest.
21:14 They've done a successful test of their antenna that it it can talk to space, but also we've attracted investment from the National Strategic Security Investment Fund and the US family office. Final assembly is expected later this year with revenues in next year. So this company has really interesting prospects this year. Wonder Health was a company that we incubated for a few years. Last year, we got direct equity exposure. And over in particular, from the second half of last year, they've had an acceleration of recurring revenue growth from several US customers. These are US health care insurance, online pharmacy players. And it it it the the guys are having a really exciting time right now just
21:55 really handling growth with The US market. And this is also a fascinating story how you can run a company on a lean budget from The UK accessing The US market. Deep Tech Recycling, they built a pipeline of projects over the last two years, and now those are paying dividends. So not not in financial sense. They're they're we're seeing results. We've had the MOU for a project in Scandinavia. There's been our term sheet provided from a Scandinavian public sector authority for up to £11,000,000 for their first plant. Now remember, this is off balance sheet. Deep Tech sets up SPVs to build plants for for plastic recycling. There's a lot of depth about each of these. There's more information in the in the annual report, but just I'm just giving you some highlights here. So for each of these companies, if you look at their market cap, there is significant growth potential as the companies get through to sales, get through to breakeven, get through to first project.
22:50 It hasn't been all smooth sailing. Another three companies, Proaxis, Glycodex, Qbot, have had challenges to overcome over the last eighteen months. Proaxis actually had a very good last year with significant growth in revenues. They cut a lot of costs, but they've had a production issue that emerged towards the end of last year, which has meant that written that they've they've had to pause the fundraise that we were planning on, and they're working to resolve that issue. At the same time, they have built a potential clinical trial launch with Imperial College, which we anticipate will launch later in the year. This is focused on COPD. So, again, the company's natural in this space. They have issues. They find problems. Where relevant, we work with them and help them work through those problems, get to the next stage, and then they resume their growth.
23:40 GlycoTest has had actually good progress in terms of moving their validation assay through a mass spec mass spec what's known as mass spectrometry validation platform. But The US life sciences markets are quite challenging, so there there's been an ongoing fundraising round that's slower than we want, and they need to close that off to accelerate growth to accelerate the market launch. So in terms of what they need to do, we're we're quite clear. It's around closing of the fundraising rounds to get them to the next stage. Now Qbot has been particularly challenging. It's a company we really believe in with an excellent technology with more than 5,000 successful retrofit installations using their robots to do retrofit installation installations in The UK and France.
24:25 Really massive market. The company last year decided to make a pivot to pivot away from a services model where they had a fairly large employment force doing direct installations towards IP and partnership and licensing model. It was a difficult turnaround. It was a
24:42 difficult pivot, which has seen the valuation of the company go down. We have played a key role in that pivot and bringing investors onto it. So the we we believe the company is turning a corner now at a much lower base. We've cut 70% costs there, significant drop in the in the in the workforce, and now the company is is is turning a corner. So what I wanna flag here is that when companies have a problem, where they get into trouble, when there is a challenge, we don't say, well, look. We've got 70 companies. We'll let these ones go. No. If we believe in the company, we engage, we help fix the problem, and then we we benefit from that. And we believe our co investors keep seeing us do this several times, so there's a growing confidence in our approach. So what's forward? Well, first of all, we've had a very busy first half of the year. There have been multiple fundraisings as you can see. Now some of you ask on the forums yes. I do read the forums.
25:35 You know,
25:37 publicize these investments. You know, why why don't you talk about them? Look. We are PLC. We have very strict rules about what is an RNS and what isn't an RNS. So we will rather be purist when we put out an RNS that it needs to fit the criteria because, otherwise, you know, where where they draw the boundaries. Through LinkedIn, you can see all of these developments. But what I want to flag is that while there isn't that much in the RNS, there is a lot of activity ongoing underneath with the businesses. So there's been a lot of fundraising work. I wish I could tell it's all success. The reality is that in today's market environment, the fundraise the rounds are smaller. It takes longer to develop them, and the investor terms are harsher. That is the reality.
26:22 However, equally in that environment, many, many companies outside of our portfolio haven't been funded at all. So the way we have approached the current environment is, look, guys, you gotta bring in the sales, cut back your business plan, have more modest more modest objectives. Let's get funding to get you to that next stage. You'll be down at a better position, and then we'll we'll we'll take it from there. So, again, without going into the details of here, each of these companies has its own story. We have helped them work through the their funding issues and get to the next stage and develop. Some of them have really accelerated like Wonder. Others are still solving issues. Deep Tech also is accelerating. Others such as CubeBot are working through their issues. But, we're there as a supportive partner helping the companies to to the next stage.
27:09 More broadly, where do we see? Well, I mean, it's it's what we said for the last two years that we have been implementing. We have grown the assets under management. We believe it will continue to grow simply through organic growth, but also through the new fund launches that we have mentioned and expansion expansion of of the The US practice. We have revenue momentum that we want to exploit. We continue to target breakeven at the core group level, which for us will be a very meaningful milestone. At that point, we become financially independent. We recognize that the market environment is chain is challenging. We did attempt to have some one exit, and we saw that the market is just not there at the moment. So instead of that, we're focusing on strategically on the companies moving through the value inflection points, selective growth, and, of course, building links with potential acquirers so that when the time is right, the time is right.
28:05 We believe we're quite well positioned over the last with with the progress over the last two years for any potential market recovery. We believe that the markets we're in, deep tech and life sciences, have strong tailwinds. It is places people want to invest in. And in particular, we're well positioned to benefit from mansion house reforms and all the related changes around that that are developing. So we know it's not all smooth sailing, but at the same time, we're resilient. What I think we have demonstrated to you over the last few years is that we can navigate challenging times well. We have a resilient model. We have multiple shots on goal, and we have multiple avenues for value creation.
28:43 So I think with that, I'm going to finish off again, you know, on the summary slide, many drivers for value, but now I look forward to hearing from your questions. Ily and Ed, thank you very much for your presentation. Ladies and gentlemen, please do continue to submit your questions just by using the q and a tab situated on the right hand corner of your screen. Just while the company take a few moments to review those questions submitted today, I'd like to remind you that recording of this presentation along with a copy of the slides and the published q and a can be accessed by investor dashboard. As you can see, we received number of questions throughout today's presentation. Please ask you to read out the questions and give response where appropriate to do so, and I'll pick up from you at the end. K. Alright. Thank you.
29:28 So so there's a few questions that I think I've covered well during the presentation. One is, could you talk a bit more about your plans to raise further AUM? Is there anything imminent? So, again, I want to emphasize, I often talk about a group of MBAs running around with a business plan, and we're raising a fund. We are not that. We have an ongoing business that organically is growing its AUM anyway. Through our years investment practice, we organically grow by at the rate of 8 to £10,000,000 of fresh cash per annum, and our companies are growing. So we're not standing still even if we're not even if a new fund isn't raised. Having said that in parallel, we have several initiatives around a new fund. It's a challenging environment to to raise a fund. We're not blind, but, equally, we feel we have something special.
30:14 In terms of is there anything imminent, you you know, it it's nothing that will crystallize in the next few months. It's a it's a sprint or a or a moderate run. It's not a 400 meters. Perhaps it's a 1,600 meters, not a 40 kilometer. K? There's there were two questions around exits. If and when there is an exit, how would you deploy the capital, and what can shareholders expect? And maybe if I turn to you, you're welcome. Yeah. Thanks, Celine. So as as we've published, our our strategy follows a evergreen model, which means that we we want to continue on the journey. So in in the event of an exit, I guess we've got a number of considerations to run through.
31:03 Look. Part part of that is reinvestment into our venture build program where we see great returns coming through as as Ilians referred to earlier In in order to launch new fund initiatives, there's often a GP stake that's required. So we we have purposes for for any exit and upside income. Obviously, the the shareholders will be keen to understand whether there's any returns coming their way. I wouldn't put us perhaps as an as an income stock. We're we're a capital growth business, but I think we certainly haven't ruled out any capital returns in in the form of dividends, buybacks, etcetera. And and it really depends, obviously, upon the size and timing of exits. So I hope hope that gives a bit of guidance that that we're flexible with no fixed policy on that.
31:54 And I think there's another question also in terms of, you know, visibility on exits and and what's on the horizon. I'll I'll refer to pro access, which we had a look at selling last year that as as we published earlier, the feedback from that that exercise was actually very positive in the sense that it gave ProAxis a great deal of inside feedback on how to grow and be more attractive to the buyers that it was talking to. Right right now, the m and a market, in our view, in in this space is pretty slow. Valuations are not what we would expect them to be, and I think our Evergreen model puts us in a very good position there. We're fortunate that we don't have a fund that we need to close-up at any particular time frame, and and we're not looking at continuation funds and all of the other things that some of our peers are looking at. So we've got the flexibility to hold until the right valuation comes about.
32:53 We're we're not just waiting. We're we're proactive investors. We're proactive managers for all of our key cohorts of companies where where they're in a venture build or value creation services program. We have a m and a readiness projects for them so that as and when the markets revive, as and when they pass through key and value inflection points, they're ready to go. They're not starting from a cold start, but they're ready to go. As and when a buyer approaches any one of these people, they've got a data room ready to go, and they're ready to launch quickly and and take full advantage of the scenario. So I think that that hopefully gives you a bit of guidance on on our m and a policy and returns policy.
33:40 Thank you, Ed. And a question from Richard. With over 70 companies now under management, how do you approach portfolio concentration risk? Well, I mean, naturally, with with with more companies, there's less concentration. I think the way we look at it is because we're not a passive investor, there's different ways of mitigation mitigating portfolio risk. There's just a natural static risk mitigation because there's more shots on goal. So, you know, even companies where we have a small percentage, let's say, someone like Citovel, you know, that we have very little day to day involvement, but we have a still, have an exposure to it. And last year, they raised 120,000,000, and it's a well known company in The US.
34:26 So, you know yeah. I mean, if there's a big exit there, we'll get we'll get some returns. So that's what most VCs look at. You know? Here is our passive portfolio. Let's let's see and pray when which something comes in. I think I think the way we see it is look, there's a passive portfolio diversification, which is nice. But because we have this proactive approach, we're also able to proactively deepen our stakes in companies that we that we like. Sometimes these are companies that are simply doing well, and we bring in some third party investment into that. And, again, being part the integration with the market practice gives us a lot more opportunities for that. We anticipate our US practice will benefit from that, this greater diversity.
35:13 And some of the feedback we've had from our EIS investors, both direct and trough EIS fund structure is, oh, that's great because within a portfolio, I get exposure both to the direct venture build where you guys where I'm taking a bet on your capability of building businesses. And within the same portfolio, I can also get a a kind of exposure or bet to companies where you're sitting alongside other bigger investors in the companies at the next stage. So there's almost for you as the shareholders on on the outside, you get to to to choose at what level you can you can you can get exposure at PLC level, at a fund level, or at a deal by deal basis. I think also us being close to the companies gives us early exposure to risk. You know, we can see the problem early on, and it enables us to take mitigation measures either to help the company avoid the problem or to prep to protect ourselves as an investor.
36:08 So, look, I don't I don't have a McKinsey style risk managements 60 page glossy report. But in a very practical way, we have this multifaceted risk management approach to our portfolio where we feel we have some advantages to others. Question from James. When do we expect to see the next readout result from the ongoing glyco test US clinical trials? So, James, excellent question and a natural one. Glycotest represents a significant part of our fair value. So glycotest, as I've talked previously, they have completed their the collection of their of their data. We have we're the proud owners of what we believe is one of the world's largest liver cancer tissue blood bank in in the world.
36:59 That in itself itself is a significant asset. What they're doing now is we are running they're running their assays through the mass spec platform with Georgia Tech University. And subject to funding, we could be seeing readouts as a you know, within this year. Again, I'll just emphasize that aspect subject to funding. And and there's various things ongoing in terms of Us us and Glock Test Management closing of the fundraise. There is an emphasize this that these are difficult markets. We can help the company continue kind of the steady ship. It's it's the big next jump that we need that's subject to funding. We're quite optimistic around it. And upon closing that, it's, you know, it's it's it's less than a year. You know? It's it's it's in the order of many months, but less than a year that they need to complete that that program.
37:54 And finally, there's a pre submitted question around evaluation methodology. What is it, and do we have confidence in these valuations? So I'm the ever optimistic CEO and entrepreneur, so maybe I'll hand over to my general counsel to give his view on the valuation methodology we use. Yeah. Sure. Thanks. Thanks, Ilian. So the the the the call to this is we follow the BBCA guidelines on how to value our portfolio. This primarily looks at the it's a reverse looking methodology, so it primarily looks at the last funding grounds for for each of the companies, and and we take fair value based upon that. In in terms of that that that that's the methodology.
38:39 In terms of our confidence levels, Ilian illustrated it very well, I think. So first and foremost, this is all subject to audit audits. So in that sense, we're very confident on the valuations. Referring back to one of his earlier slides, so I think we we see upside upon those valuations. So we're as an optimist myself, I think we're we're really looking at the valuations as the baseline here because they're reverse looking. So in the meantime, since the company's last fundraising, generally, with with our companies being in high grade space continue that high growth. We're we're expecting them to grow rather than reduce. So we're we're expecting values to go up rather than to go down.
39:24 And we're looking at some things that haven't been incorporated in the valuation methodology from the BECA. So think things like that that growth that I've mentioned between a a fundraising and current dates, things like carried interest, things like goodwill in our own business and the fact that we're revenue generating in our own rights, all of those things aren't incorporated into the valuations and the fair values that you've seen in the financial slides. So we have a great deal of confidence there, and we we think there's hidden value, which has been commented on by other financial commentators in the market. Thanks, Ed. And a question from James Kay. Our investment in Deep Tech Recycling looks incredibly exciting.
40:10 Can you expand on the pilot plant, MOU, and which countries are involved? And, James, I I also created it's a really exciting business. And as you know, we've had I've had long term exposure to the deep tech recycling story, including the predecessor company from which we acquired the asset or from their administrators. I mean, first of all, would say this is the right time for for for plastic chemical recycling. You know, the the concept has been around for a long time. Now we can see both on a regulatory and commercial basis, the recognition that this is the way. And what we've seen with the deep tech recycling team is that they're having a lot of interest in inbound interest from real users, you know, real players. It's not it's not it's not the I don't mean this in a disparaging way, but it's not the ESG department or big corporate.
41:03 Let's spend a bit of time to see it. These are real players, mid mid market companies in the in in Europe that are looking at, actually, we need a solution now because there's a specific regulatory framework coming in. So the first thing I wanna emphasize with deep tech is that they have a pipeline of opportunities. They've learned from the past. So there is a diversification of opportunities. And at any point in time, one pilot one plant opportunity accelerates, another one slows down. But few months later, the other one has a breakthrough. So we're not they're not dependent on any one any one opportunity. Scandinavian opportunity in particular is very, very interesting. I don't wanna mention the country because it's it's it will it will put the management team in a in a uncomfortable position. It's we we're in the middle of negotiations there on the go forward.
41:51 But, essentially, this would see a full commercial plant operating off balance sheet for Deep Tech. It's an SPV that's formed in that jurisdiction, and the SPV has been formed between Deep Tech and the other two partners funded at SPV level, not by Deep Tech Recycling, but by third parties there. Deep Tech Recycling itself is looking to contribute to the most both assets that we acquired. So there is a crystallization of assets through that in the in the in the many millions. From the from the partner's perspective, they also win because it accelerates the project. It will take more than a year, pass possibly two years to build out that equipment, and it's there.
42:37 It's ready ready to move forward. Having to say having said that, look, it's project finance. It's a a a a complex space, so these things naturally take time to negotiate, build out, and develop. And in in in the same time, we're building out several other opportunities in parallel. We're quite we're quite optimistic. I'll say one more thing about Deep Tech Recycling. The if you look at companies such as Agilix, let's say, which are listed on the Oslo stock exchange, you can see the valuation uplift that having one operating plan plan gives you. And deep tech recycling has a route to more than one plants with the current pipeline. So we expect significant value uplift from where we are right now once the plant has been launched and enter the potential for M and A at that point.
43:27 There's two more questions. One is around shareholder value and strategy from Stefan. What strategy do you do you plan to employ to ensure shareholder value is reflected in the share price? Well, I mean, a lot of it is what we're doing right now, just having a, how can I say, a very streetwise real discussion about, look, this is what this business is? You know, we could fill it with jargon, but bottom line is it's people doing work with real companies doing real things. I think there's an element here that perhaps we need to get better and more frequent at communicating with the market what is happening. It's like some of the really significant developments don't meet the technical criteria for an RNS, so it's making more use of periodic statements and LinkedIn.
44:18 Ultimately, we know that the market ultimately wants us to do one cycle to have an exit to show that the whole cycle works. I would say with the expanded portfolio, including the market capital portfolio, the opportunities for exits are increasing continuously. And at the same time, we are focused on also maximizing value. We don't want to just have us exit for the sake of it because then you won't be happy that we sold it for a lower lower price, but it's on on these different levels. And so there's a question by Chris. Given the large discounts to n a of NAV to to value, do you have any concerns with regards to a takeover of EMV? Very good question. Look. We're a publicly listed company and, you know, the rules are the rules. From our from our perspective, we are focused on running on on delivering on our strategy and implementing it well.
45:14 For the rest of it, you know, I think we have a strong standalone strategy for us to for us to execute. I would flip it the other way that a realignment of our value with our with our share price perhaps makes it easier for us to do interesting things on the market, and so that's certainly something that hasn't escaped our attention. I'd I'd probably just add to that, Ilian, that looking at our shareholder capital table as we had in our earlier slides, the pie charts, you know, that that there's a a a diverse holding that the management team has around 17%.
45:59 There are other large shareholders. So clearly, kind of takeover offer would require peep people to be on board with it, and and that could be a a good thing as well as as a concerning thing. So, obviously, it all depends upon the the price that we're what's be tabled. But, anyway, all very hypothetical, but, hopefully, not a concern. We're we're certainly not concerned. Thank you, Ed. Okay. Well, I think maybe with that, we will conclude. Appreciate your patience. We're just a few minutes over our limit. Thank you for your support. Again, these slides will be both live on the IMC and on our website. Please continue to engage with us. We for regulatory reasons, we can't always respond in a very public manner, but we do we do listen. We do we do we do read. We want to know what you think about. Ultimately, you are our shareholders.
46:57 And, you know, hang on for for the rest of the story to unfold. Gillian, Ed, thank you for updating investors today. Please ask investors not to close this session as you'll now be automatically redirected to provide your feedback in order that the management team can better understand your views and expectations. This will only take a few moments to complete, and I'm sure will be greatly valued by the company. On behalf of the management team of EMV CAPITAL PLC, we'd like to thank you for attending today's presentation, and good morning to you all.
Follow EMV Capital PLC into a list and get an email when it puts out news.
CEO at EMV CAPITAL PLC
Executive Director at EMV CAPITAL PLC